Systematic reviews and meta-analyses have made a major contribution to the evidence-based management of infections in cancer patients. We review the contribution of systematic reviews with regard to antibiotic, antifungal, antiviral and Pneumocystis pneumonia prophylaxis; antibiotic and antifungal treatment of febrile neutropenia; use of intravenous immunoglobulins, and infection control strategies during neutropenia. We focus on limitations of randomized controlled trials and the way systematic reviews have addressed and resolved some of these limitations. Systematic reviews allow us to ask the right clinical question; consider the most relevant clinical outcome; address the problem of small trials and rare outcomes; address external validity and bias in randomized controlled trials, and point at gaps in evidence.

Keywords:
Antibiotics, Antifungals, Antivirals, Infection control, Meta-analysis, Prophylaxis, Systematic review
1.
Pizzo PA, Hathorn JW, Hiemenz J, Browne M, Commers J, Cotton D, Gress J, Longo D, Marshall D, McKnight J, Rubin M, Skelton J, Thaler M, Wesley R: A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N Engl J Med 1986;315:552–558.
2.
Giamarellou H: Aminoglycosides plus beta-lactams against gram-negative organisms. Evaluation of in vitro synergy and chemical interactions. Am J Med 1986;80:126–137.
3.
Klastersky J, Meunier-Carpentier F, Prevost JM, Staquet M: Synergism between amikacin and cefazolin against Klebsiella: in vitro studies and effect on the bactericidal activity of serum. J Infect Dis 1976;134:271–276.
4.
Klastersky J, Zinner SH: Synergistic combinations of antibiotics in gram-negative bacillary infections. Rev Infect Dis 1982;4:294–301.
5.
Paul M, Soares-Weiser K, Grozinsky S, Leibovici L: Beta-lactam versus beta-lactam-aminoglycoside combination therapy in cancer patients with neutropaenia. Cochrane Database Syst Rev 2003;3:CD003038.
6.
Paul M, Soares-Weiser K, Leibovici L: Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for fever with neutropenia: systematic review and meta-analysis. BMJ 2003;326:1111.
7.
Yahav D, Gafter-Gvili A, Muchtar E, Skalsky K, Kariv G, Yeshurun M, Leibovici L, Paul M: Antiviral prophylaxis in haematological patients: systematic review and meta-analysis. Eur J Cancer 2009;45:3131–3148.
8.
Gafter-Gvili A, Fraser A, Paul M, Leibovici L: Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients. Ann Intern Med 2005;142:979–995.
9.
Gafter-Gvili A, Fraser A, Paul M, van de Wetering M, Kremer L, Leibovici L: Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy. Cochrane Database Syst Rev 2005;4:CD004386.
10.
Gafter-Gvili A, Paul M, Fraser A, Leibovici L: Effect of quinolone prophylaxis in afebrile neutropenic patients on microbial resistance: systematic review and meta-analysis. J Antimicrob Chemother 2007;59:5–22.
11.
Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, Feld R, Pizzo PA, Rolston KV, Shenep JL, Young LS: 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002;34:730–751.
12.
Bucaneve G, Castagnola E, Viscoli C, Leibovici L, Menichetti F: Quinolone prophylaxis for bacterial infections in afebrile high risk neutropenic patients. Eur J Cancer 20075:5–12.
13.
Paul M, Yahav D, Fraser A, Leibovici L: Empirical antibiotic monotherapy for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother2006;57:176–189.
14.
Paul M, Yahav D, Fraser A, Leibovici L: Anti-pseudomonal beta-lactam monotherapy for the initial, empirical, treatment of febrile neutropenia: comparison of beta-lactams (intervention protocol, full updated review to be published). Cochrane Database Syst Rev2007;4:CD005197.
15.
Yahav D, Paul M, Fraser A, Sarid N, Leibovici L: Efficacy and safety of cefepime: a systematic review and meta-analysis. Lancet Infect Dis 2007;7:338–348.
16.
US Food and Drug Administration: Information for Healthcare Professionals: Cefepime (marketed as Maxipime). 2009. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm167254.htm.
17.
Paul M, Borok S, Fraser A, Vidal L, Cohen M, Leibovici L: Additional anti-Gram-positive antibiotic treatment for febrile neutropenic cancer patients. Cochrane Database Syst Rev 2005;3:CD003914.
18.
Paul M, Borok S, Fraser A, Vidal L, Leibovici L: Empirical antibiotics against Gram-positive infections for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother 2005;55:436–444.
19.
Robenshtok E, Gafter-Gvili A, Goldberg E, Weinberger M, Yeshurun M, Leibovici L, Paul M: Antifungal prophylaxis in cancer patients after chemotherapy or hematopoietic stem-cell transplantation: systematic review and meta-analysis. J Clin Oncol2007;25:5471–5489.
20.
Goldberg E, Gafter-Gvili A, Robenshtok E, Leibovici L, Paul M: Empirical antifungal therapy for patients with neutropenia and persistent fever: systematic review and meta-analysis. Eur J Cancer 2008;44:2192–2203.
21.
Raanani P, Gafter-Gvili A, Paul M, Ben-Bassat I, Leibovici L, Shpilberg O: Immunoglobulin prophylaxis in hematopoietic stem cell transplantation: systematic review and meta-analysis. J Clin Oncol 2009;27:770–781.
22.
Raanani P, Gafter-Gvili A, Paul M, Ben- Bassat I, Leibovici L, Shpilberg O: Immunoglobulin prophylaxis in hematological malignancies and hematopoietic stem cell transplantation. Cochrane Database Syst Rev2008;4:CD006501.
23.
Leibovici L, Paul M, Cullen M, Bucaneve G, Gafter-Gvili A, Fraser A, Kern WV: Antibiotic prophylaxis in neutropenic patients: new evidence, practical decisions. Cancer2006;107:1743–1751.
24.
Bucaneve G, Micozzi A, Menichetti F, Martino P, Dionisi MS, Martinelli G, Allione B, D’Antonio D, Buelli M, Nosari AM, Cilloni D, Zuffa E, Cantaffa R, Specchia G, Amadori S, Fabbiano F, Deliliers GL, Lauria F, Foà R, Del Favero A, Gruppo Italiano Malattie Ematologiche dell’Adulto (GIMEMA) Infection Program: Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med 2005;353:977–987.
25.
Cullen M, Steven N, Billingham L, Gaunt C, Hastings M, Simmonds P, Stuart N, Rea D, Bower M, Fernando I, Huddart R, Gollins S, Stanley A; Simple Investigation in Neutropenic Individuals of the Frequency of Infection after Chemotherapy +/– Antibiotic in a Number of Tumours (SIGNIFICANT) Trial Group: Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. N Engl J Med2005;353:988–998.
26.
Vidal L, Paul M, Ben dor I, Soares-Weiser K, Leibovici L: Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients: a systematic review and meta-analysis of randomized trials. J Antimicrob Chemother2004;54:29–37.
27.
Vidal L, Paul M, Ben-Dor I, Pokroy E, Soares-Weiser K, Leibovici L: Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients. Cochrane Database Syst Rev 2004;4:CD003992.
28.
Schlesinger A, Paul M, Gafter-Gvili A, Rubinovitch B, Leibovici L: Infection-control interventions for cancer patients after chemotherapy: a systematic review and meta- analysis. Lancet Infect Dis2009;9:97–107.
29.
Raanani P, Gafter-Gvili A, Paul M, Ben-Bassat I, Leibovici L, Shpilberg O: Immunoglobulin prophylaxis in chronic lymphocytic leukemia and multiple myeloma: systematic review and meta-analysis. Leuk Lymphoma 2009;50:764–772.
30.
Consensus on IVIG. Lancet 1990;336:470–472.
31.
Green H, Paul M, Vidal L, Leibovici L: Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients. Cochrane Database Syst Rev 2007;3:CD005590.
32.
Green H, Paul M, Vidal L, Leibovici L: Prophylaxis of Pneumocystis pneumonia in immunocompromised non-HIV-infected patients: systematic review and meta-analysis of randomized controlled trials. Mayo Clin Proc2007;82:1052–1059.
33.
Paul M, Leibovici L: Systematic reviews and meta-analysis of febrile neutropenia. Mayo Clin Proc2005;80:1122–1125.
34.
Higgins JPT, Green S (eds): Cochrane Handbook for Systematic Reviews of Interventions, version 5.0.2 (updated September 2009). The Cochrane Collaboration, 2008. www.cochrane-handbook.org.
© 2010 S. Karger AG, Basel
2010
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.